In a small clinical study run in China, reports Stat News, patients were treated with a slightly modified version of an approved CAR-T saw benefits on par with pervious studies but with none of the well-known side effects that can hospitalize patients.  If this study’s results can be replicated CAR-T can be safer and more available to many more patients. Follow the link to read the entire Stat News story.

Lead Research/Investigator

Dr. Si-Hi Chen, professor of immunology, University of Southern California

Source: Statnews

Pin It on Pinterest